Sensitization to isobornyl acrylate in a tertiary Belgian hospital.

Allergic contact dermatitis (ACD) to isobornyl acrylate (IBOA) hasbeen largely reported. Consequently, it was recognized as the“Con-tact Allergen of the Year 2020â€by the American Contact DermatitisSociety. The prevalence of IBOA sensitization is estimated to be 0.7%to 3.8% in patients with adverse skin reactions to medical devices(MDs) used in diabetes.1,2However, to our knowledge, the prevalenceof sensitization to IBOA in the general patch-tested population hasnot yet been established. [.]